AOA Dx & Biosis Ventures: Investing in AOA Dx Inc is investing in the future of women’s health.

With teams in Boston, New York and London, AOA Dx is focused on developing cutting-edge cancer diagnostics in the field of women’s health, including a liquid biopsy test for early-stage diagnosis of ovarian cancer. The blood test will diagnose by detecting tumor biomarkers and has shown promising results in preliminary testing for both pre and postmenopausal individuals.

• Early diagnosis can save up to 100,000 women per year
• 94% of women experience symptoms starting from Stage 1
• 80% of cases are diagnosed too late
• Typical symptoms are abdominal pain and bloating, leading to lengthy diagnoses and often unnecessary procedures
• This disease is on the rise, impacting at least 1 in 78 women in their lifetime and expected to grow by 55% by 2035

AOA Dx is revolutionizing early-stage diagnosis of ovarian cancer through a non-invasive ovarian cancer diagnostic liquid biopsy test that utilizes proprietary antibodies to detect gangliosides specific to cancer. These gangliosides are stable non- mutating targets present in the cancer cycle and during relapse, which make them an optimal target for early cancer detection. AOA Dx is improving clinical practice by diagnosing ovarian cancer early, reducing patient mortality and delivering cost savings to payers.

We are proud to be supporting an incredible team working on solutions to problems in diagnostics. AOA Dx does just that, building tech that will lay the foundation for improvement in diagnostics. We look forward to playing a role in funding AOA Dx’s mission as part of their $5M seed round to advance the availability of life-saving health technologies.